Enterprise Value
-40.75M
Cash
82.06M
Avg Qtr Burn
-9.326M
Short % of Float
2.44%
Insider Ownership
17.71%
Institutional Own.
34.78%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NL-201 (IL-2 and IL-15 agonist) Details Solid tumor/s, Cancer | Failed Discontinued |